Right now, we are working as the ‘virtual pharmacovigilance office’ for many of the most dynamic healthcare manufacturers in the […]
At Acorn Regulatory we are committed to ensuring quality in all aspects of what we do so it’s vital to […]
Minister Simon Harris’ confirmation that the Irish government will soon be making a bid to be the new home of […]
We have just launched our new Acorn Regulatory monthly newsletter. You can read all of the stories from the newsletter […]
In this article we are taking a look at 3 key factors to consider when planning to in-licence an eCTD dossier. […]
The implications of Brexit are still being felt. Politically, the decision has triggered a chain of events that none of us […]
Perhaps one of the most frequently asked questions that our team members get is “how do you get started in […]
In this month’s roundup of industry news roundup, we will be looking at how the USA and Canada are working […]
Right now, we are seeking a consultant to work on-site with our client in the south-east of Ireland. The client is […]
In this extract from our first Brexit whitepaper we look at the implications of Brexit for the medical device sector.
The European Medicines Agency has added a new chapter (Product- or population-specific considerations II: Biological medicinal products) to its guidelines […]
In this extract from our first Brexit whitepaper we look at the implications of Brexit for the clinical trials sector.